Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation
| Autor: | Ketty Peris, Maria Concetta Fargnoli, S D'Adamio, Sara Tambone, Marco Galluzzo, Gaia Moretta, Giacomo Caldarola, Clara De Simone, Marina Talamonti, Luca Bianchi |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male Moderate to severe medicine.medical_specialty PASI100 Clinical Biochemistry Antibodies Monoclonal Humanized Severity of Illness Index Young Adult 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine real life Internal medicine Drug Discovery medicine Humans biologic drugs Aged Retrospective Studies Plaque psoriasis Pharmacology Biological Products business.industry secukinumab Drug Discovery3003 Pharmaceutical Science Interleukin-17 Antibodies Monoclonal psoriasis Middle Aged Large cohort Treatment Outcome Italy 030220 oncology & carcinogenesis Female Secukinumab Life study business Settore MED/35 - MALATTIE CUTANEE E VENEREE Anti-IL-17 |
| DOI: | 10.6084/m9.figshare.6803621 |
| Popis: | Objectives: To evaluate efficacy and safety of the anti-IL-17 drug secukinumab in a real-life large cohort of patients with moderate-to-severe plaque psoriasis in Central Italy. Methods: Multicenter, retrospective study with an observation period of up to 52 weeks. Efficacy was assessed by Psoriasis Area and Severity Index (PASI) score; clinical and laboratory examinations were performed at baseline and at weeks 4, 12, 24, 36, and 52. Results: A 90% and a 100% PASI score reduction (PASI90 and PASI100) were reported in 67.5% and 55% of patients at week 12, respectively. A rapid improvement of skin lesions was observed particularly in young patients and in patients naïve to biologics: at week 4, the achievement of PASI90 and PASI100 was higher in younger patients (odds ratio [OR] 0.95, and 0.95; p = 0.003, and 0.005, respectively); PASI90 was achieved by 42.0% of patients naïve to biologics and by 17.0% of patients with prior exposure to biologics (PBT) (OR 0.24; p = 0.001); and PASI100 was reached by 25.5% of naïve patients and 9.8% of PBT (OR 0.28; p = 0.015).The drug was well tolerated. Conclusion: Secukinumab was effective in this real-life analysis, with rapid clinical improvement and long-term maintenance of results. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|